Schizophrenia Sensory Gating Deficit With Quetiapine

• Status: Completed
• Trial end date: 2006-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is the use of magnetoencephalography or MEG (a machine that measures magnetic activity in your brain) and electroencephalography or EEG (a technique that measures electrical activity in your brain) to study how sounds are processed in individuals with schizophrenia after three months of taking the antipsychotic medication quetiapine.

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: New Mexico VA Healthcare System
• Collaborator: AstraZeneca
• Treatments: Quetiapine Fumarate

Criteria

Inclusion Criteria:

Patient Population

• Diagnosis of Schizophrenia as determine by the Structured Clinical Interview for DSM-IV

• No comorbid diagnosis of PTSD

• responders to quetiapine, determined by continuous treatment at the same dose of quetiapine and absence of psychiatric hospitalization for at least 3 months

• No history of drug dependency in their lifetime

• No history of alcohol or other substance abuse in the 6 months prior to entry into the study

• No history of head injury with loss of consciousness for more than 5 minutes

• No history of seizure disorder

• No mood stabilizing agents

• Between 18-65 and

• Able to sign informed consent

Normal Controls

• Matched in age and gender to patient population

• No history of psychiatric dysfunction or alcohol or other substance dependence in their lifetime as determine by the SCID

• No history of alcohol or other substance abuse in the previous 6 months

• No family history of psychotic disorder in first degree relatives as assessed by the FH-RDC diagnostic interview

• No history of head injury with loss of consciousness for more than 5 minutes

• No history of seizure disorder

• Between 18-65

• Able to sign informed consent

Exclusion Criteria:

Subjects will be excluded from participating in this study if they:

• Require treatment with a mood stabilizer

• Have had an inpatient hospitalization in the past 3 months

• Have a history of a neurological disorder

• Have any other axis I diagnosis besides schizophrenia